The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
Abstract
To completely eliminate androgens of both testicular and adrenal origin, 37 previously untreated patients with advanced (stages C or D) prostatic cancer received the combination therapy using an LHRH agonist (HOE‐766) and a pure antiandrogen (RU‐23908). The response criteria developed by the National Prostatic Cancer Project were used. A positive response (assessed by bone scan and/or serum prostatic acid phosphatase measured by radioimunoassay was observed in 29 of the 30 cases who could be evaluated by these objective criteria (97%). The objective response was parallel to a rapid and marked improvement of the clinical signs and symptoms related to prostate cancer (prostatism, bone pain, and general well being). In marked contrast, the same combination therapy applied to patients previously treated with high doses of diethylstilbestrol (13 patients) showed a positive objective response in only 55% of cases. In 23 previously castrated patients showing relapse, an objective response was seen in only 25% of cases after neutralization of adrenal androgens by the antiandrogen. Previous treatment with chlorotrianisene (TACE) had no detectable effect on prostatic cancer and patients having previously received such treatment had a rate of positive response similar to previously untreated patients (five of five). In the previously untreated patients receiving the combination therapy, a 60% fall in serum prostatic acid phosphatase was observed as early as five days after starting treatment, at a time when the serum androgen concentration was 100% to 200% above control. Combined treatment with the pure antiandrogen completely prevents flare‐up of the disease, a complication previously found in a significant proportion of patients treated with an LHRH agonist alone. The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy (castration or high doses of estrogens). Adrenal androgens are most likely responsible for this difference. The present study also shows that the proportion of androgen‐sensitive cells decreases from more than 95% in untreated patients to 25% to 55% after previous partial hormonal therapy. Such data clearly indicate that the previous partial hormonal therapy exclusively aimed at neutralizing testicular androgens left 25% to 55% of cancer cells having a relatively low sensitivity to adrogens in a hormonal milieu compatible with their continuous growth. No clinical or biochemical side effect could be detected except those related to reduced serum androgen levels. Due to the ease of its application and the lack of secondary effects other than those related to hypoandrogenicity, the present data clearly suggest that complete (instead of partial) androgen withdrawal should be performed as early as possible after diagnosis, at least in advanced prostatic cancer, to reduce the development of androgen‐insensitive cell clones and to facilitate the adjuvant treatment with chemotherapeutic agents and/or radiotherapy of androgen‐insensitive tumors in the appropriate cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
Extension of Multiple Range Tests to Group Means with Unequal Numbers of Replications
Kramer, C. Y. (1956) · Biometrics · doi:10.2307/3001469 · Cited by 3,146
HUGGINS, C. (1941) · Archives of Surgery · doi:10.1001/archsurg.1941.01210140043004 · Cited by 1,499
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c · Cited by 597
ENDOCRINE CONTROL OF PROSTATIC CARCINOMA: Clinical and Statistical Survey of 1,818 Cases
NESBIT, R. M. (1950) · Journal of the American Medical Association · doi:10.1001/jama.1950.02910500019005 · Cited by 371
Huggins, C., & Scott, W. W. (1945) · Annals of Surgery · doi:10.1097/00000658-194512260-00012 · Cited by 346
Labrie, F., Dupont, A., Bèlanger, A., Cusan, L., Lacourcière, Y., Monfette, G., LaBerge, J., Emond, J., Fazekas, A. T. A., Raynaud, J., et al. (1982) · PubMed · Cited by 276
Self-citationThe Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone
Fowler, J. E., & Whitmore, W. F. (1981) · Journal of Urology · doi:10.1016/s0022-5347(17)54531-0 · Cited by 261
Bailar, J. C., Byar, D. P., & The veterans administration cooperative urological research group (1970) · Cancer · doi:10.1002/1097-0142(197008)26:2<257::aid-cncr2820260203>3.0.co;2-9 · Cited by 244
Carcinoma of the Prostate: Treatment Comparisons
The Veterans Administration Cooperative Urological Research Group S0022534717629264-57c401330b4195dbd1713587ed540477 Lino J. Arduino Veterans Administration Hospital (VAH), D. M. (1967) · Journal of Urology · doi:10.1016/s0022-5347(17)62926-4 · Cited by 210
Cited by
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
Steroid sulfatase: molecular biology, regulation, and inhibition
Reed, M. J., Purohit, A., Woo, L. W. L., Newman, S. P., & Potter, B. V. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0003 · Cited by 524
Carlin, B. I., & Andriole, G. L. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.0.co;2-q · Cited by 363
Chen, Y., Clegg, N. J., & Scher, H. I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70229-3 · Cited by 324
Metadata
- Authors
- Labrie, F., Dupont, A., Belanger, A., Lacoursiere, Y., Raynaud, J. P., Husson, J. M., Gareau, J., Fazekas, A. T. A., Sandow, J., Monfette, G., Girard, J. G., Emond, J., & Houle, J. G.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 1983-01
- Volume
- 4
- Issue
- 6
- Pages
- 579-594
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2074613446
- Cited by
- 290
- References
- 24
- FWCI
- 22.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.